Pharma industry spending on lobbying exploded in 2018

The trade group for the U.S.'s top drugmakers spent a record amount––$27.5 million––on lobbying efforts in 2018, according to Bloomberg.

The spending, which was disclosed by the Pharmaceutical Research and Manufacturers of America (PhRMA), was $1.4 million more than what was reported in 2009, when the Affordable Care Act was crafted. The association spent nearly $10 million during the first three months of 2018 to lobby Congress and the Trump administration—its biggest-ever quarter, Bloomberg reported. More than $6 million was spent on lobbying efforts in the fourth quarter of 2018.

The spending surge was a reaction to the potentially “most challenging year in decades” for the industry.

The lobbying disclosure comes at a time when rising drug prices have garnered negative attention from President Trump, lawmakers and consumers. For example, the cost of managing diabetes has increased significantly from 2012 to 2016, according to a recent report.

The Trump administration has ramped up efforts to lower drug prices, while House Democrats launched an investigation into rising prices.

See the full story below:  

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.